share_log

Altamira Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Thomas Meyer(1.2%)

Altamira Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)

Altamira Therapeutics | SC 13D/A：超过5%持股股东披露文件(修正)
SEC announcement ·  03/13 11:08
Moomoo AI 已提取核心信息
Thomas Meyer, an investor in Altamira Therapeutics, has filed an amendment to his Schedule 13D with the U.S. Securities and Exchange Commission, disclosing recent purchases of the company's common stock. The amendment, dated March 13, 2024, reports that Meyer now beneficially owns 22,297 common shares of Altamira Therapeutics, which represents 1.2% of the company. This stake includes 20,000 common shares and the right to acquire an additional 2,297 shares through options and warrants exercisable within 60 days. The filing details two separate transactions: the purchase of 51 common shares on December 29, 2023, at $3.24 per share, and 17,350 common shares on March 11, 2024, at $1.864 per share, both funded with personal funds. Meyer holds sole voting and dispositive power over these shares. The amendment to Schedule 13D does not alter any previously reported information except as explicitly stated.
Thomas Meyer, an investor in Altamira Therapeutics, has filed an amendment to his Schedule 13D with the U.S. Securities and Exchange Commission, disclosing recent purchases of the company's common stock. The amendment, dated March 13, 2024, reports that Meyer now beneficially owns 22,297 common shares of Altamira Therapeutics, which represents 1.2% of the company. This stake includes 20,000 common shares and the right to acquire an additional 2,297 shares through options and warrants exercisable within 60 days. The filing details two separate transactions: the purchase of 51 common shares on December 29, 2023, at $3.24 per share, and 17,350 common shares on March 11, 2024, at $1.864 per share, both funded with personal funds. Meyer holds sole voting and dispositive power over these shares. The amendment to Schedule 13D does not alter any previously reported information except as explicitly stated.
Altamira Therapeutics的投资者托马斯·迈耶已向美国证券交易委员会提交了附表13D的修正案，披露了最近购买该公司普通股的情况。该修正案于2024年3月13日发布，报告称，迈耶现在实益拥有Altamira Therapeutics的22,297股普通股，占该公司1.2％的股份。该股份包括20,000股普通股以及通过可在60天内行使的期权和认股权证额外收购2,297股的权利。该文件详细介绍了两笔单独的交易：2023年12月29日以每股3.24美元的价格购买51股普通股，以及2024年3月11日以每股1.864美元的价格购买17,350股普通股，均由个人资金资助。迈耶对这些股票拥有唯一的投票权和处置权。除非另有明确说明，否则附表13D的修正不会改变任何先前报告的信息。
Altamira Therapeutics的投资者托马斯·迈耶已向美国证券交易委员会提交了附表13D的修正案，披露了最近购买该公司普通股的情况。该修正案于2024年3月13日发布，报告称，迈耶现在实益拥有Altamira Therapeutics的22,297股普通股，占该公司1.2％的股份。该股份包括20,000股普通股以及通过可在60天内行使的期权和认股权证额外收购2,297股的权利。该文件详细介绍了两笔单独的交易：2023年12月29日以每股3.24美元的价格购买51股普通股，以及2024年3月11日以每股1.864美元的价格购买17,350股普通股，均由个人资金资助。迈耶对这些股票拥有唯一的投票权和处置权。除非另有明确说明，否则附表13D的修正不会改变任何先前报告的信息。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息